Argenx declares Phase 3 win for Vyvgart Hytrulo in autoimmune myositis
Phase 3positiveVyvgart HytruloPositive
AI Analysis
Summary
Argenx announced that Vyvgart Hytrulo met its Phase 3 primary endpoint in autoimmune myositis, though the drug failed to achieve the primary endpoint in a key patient subgroup.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Not Met
Outcome Details
Phase 3 test passed in autoimmune myositis; however, drug missed primary endpoint in a key patient subgroup
Importance:8/10
Sentiment:
0.60
Phase 3autoimmunerare diseasesubcutaneous
Related Companies
Read the original article
Published by Endpoints News on August 17, 2026 10:51 AM